DAVID W J MCGIRR
CIK 1219023 · SVP & Chief Financial Officer · last filed 2026-06-25
DAVID W J MCGIRR is a SVP & Chief Financial Officer who has filed 79 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for RYTM, was dated Jun 25, 2026. Across all open-market trades the lifetime net is −$10.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $14.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$14.54M
9
79
-$10.94M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RYTM | Director | 11,712 | $115.48 | $1.35M | -$4.27M | 12 | 2026-06-25 |
| INSM | Director | 97,723 | $134.75 | $13.17M | -$451.5K | 16 | 2026-02-11 |
| XFOR | Director | 4,722 | $4.25 | $20.1K | $0 | 7 | 2025-06-10 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | — | — | — | $0 | 2 | 2019-08-08 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | Director | — | $0.08 | — | $0 | 3 | 2018-06-07 |
| Roka BioScience, Inc. (ROKA) Delisted | Director | 5,000 | — | — | $180.1K | 4 | 2017-06-30 |
| Relypsa Inc (RLYP) Delisted | Director | 2,250 | — | — | -$61.9K | 5 | 2016-09-02 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | SVP & Chief Financial Officer | 23,980 | — | — | -$6.34M | 26 | 2013-02-20 |
| LIFECELL CORP (VITA) Delisted | Director | — | — | — | $0 | 1 | 2008-06-04 |
Recent Filings
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-25 | RYTM | Mixed | +4,712 | $0 | EDGAR |
| 2026-02-11 | INSM | Gift (G) | — | $0 | EDGAR |
| 2025-06-26 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2025-06-23 | RYTM | Exer (M) | +4,000 | $0 | EDGAR |
| 2025-06-10 | XFOR | Grant (A) | +1,500 | $0 | EDGAR |
| 2025-06-05 | RYTM | Mixed | — | -$3.97M | EDGAR |
| 2025-06-04 | INSM | Sell (S) | −6,250 | -$451.5K | EDGAR |
| 2025-06-04 | INSM | Notice (144) | −3,000 | -$219.8K | EDGAR |
| 2025-06-03 | RYTM | Notice (144) | −65,431 | -$4.17M | EDGAR |
| 2025-06-03 | INSM | Notice (144) | −3,250 | -$231.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.